Evidence map›Paper›PMID 29884223›Full record

Trial reportArthritis research & therapy2018

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.

Elodie Rivière, Jérémie Sellam, Juliette Pascaud, Philippe Ravaud, Jacques-Eric Gottenberg, Xavier Mariette

Registry-linked trialOpen access · goldAbstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01000441 (Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01000441 phase4completednot on this map

Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

TypeinterventionalSponsorUniversity Hospital, Strasbourg, FranceRan2009 to 2013Enrolled300ConditionsRheumatoid ArthritisArmsinfliximab, etanercept, adalimumab, abatacept, rituximab or tocilizumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases.International journal of molecular sciences · 2019
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Elodie RivièreImmunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM UMR1184, Le Kremlin Bicêtre & Fontenay aux Roses, France.
Jérémie SellamDepartment of Rheumatology, Saint-Antoine Hospital, Université Paris 6, INSERM UMRS 938, DHU i2B, Paris, France.
Juliette PascaudImmunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM UMR1184, Le Kremlin Bicêtre & Fontenay aux Roses, France.
Philippe RavaudDepartment of Epidemiology and Biostatistics, Hotel Dieu, Paris, France.
Jacques-Eric GottenbergDepartment of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Strasbourg University Hospital, Université de Strasbourg, Strasbourg, France.
Xavier MarietteImmunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM UMR1184, Le Kremlin Bicêtre & Fontenay aux Roses, France. xavier.mariette@aphp.fr.
Université Paris-Sud · FRHôtel-Dieu de Paris · FRInserm · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registrationRotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC), registered 22 October 2009, NCT01000441.

Indexed as

AbataceptAdalimumabAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidBiological FactorsEtanerceptFemaleHumansInfliximabInterleukin-33MaleMiddle AgedRituximabAbataceptAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsBiological FactorsEtanerceptInfliximabInterleukin-33RituximabtocilizumabBiologic agentsInterleukin 33Personalized medicineRheumatoid arthritis

Identifiers

PMID29884223
PMCPMC5994091
OpenAlexW2805271366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.